Skip to content
10-Q/A

Quarterly Report

NIKA PHARMACEUTICALS, INC NIKA

0001826466-24-000136

← back to feed
Filed
Nov 1, 2024 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Oct 25, 2024 1.02B sh
Shares Diluted Q2 2024 · Jun 30, 2024 1.02B sh
Shares Diluted Q2 2024 · Jun 30, 2024 1.02B sh
Shares Diluted Q2 2024 · Jun 30, 2023 876.09M sh
Shares Diluted Q2 2024 · Jun 30, 2023 876.09M sh
Operating Cash Flow restated Q2 2024 · Jun 30, 2024 −$523.07K
Operating Cash Flow restated Q2 2024 · Jun 30, 2023 −$47.38K
Short Term Debt Q2 2024 · Jun 30, 2024 $632.3K
Short Term Debt Q2 2024 · Dec 31, 2023 $101.75K
Cash And Equivalents restated Q2 2024 · Jun 30, 2024 $7.49K
Cash And Equivalents restated Q2 2024 · Dec 31, 2023 $19.6K
Stockholders Equity restated Q2 2024 · Jun 30, 2024 −$246.61K
Stockholders Equity restated Q2 2024 · Mar 31, 2024 −$225.48K
Stockholders Equity restated Q2 2024 · Dec 31, 2023 −$82.15K
Stockholders Equity Q2 2024 · Jun 30, 2023 −$64.69K
Stockholders Equity Q2 2024 · Mar 31, 2023 −$36.89K
Stockholders Equity Q2 2024 · Dec 31, 2022 −$17.32K
Current Liabilities restated Q2 2024 · Jun 30, 2024 $636.93K
Current Liabilities restated Q2 2024 · Dec 31, 2023 $101.75K
Total Liabilities restated Q2 2024 · Jun 30, 2024 $636.93K
Total Liabilities restated Q2 2024 · Dec 31, 2023 $101.75K
Current Assets Q2 2024 · Jun 30, 2024 $222.06K
Current Assets restated Q2 2024 · Dec 31, 2023 $19.6K
Total Assets restated Q2 2024 · Jun 30, 2024 $390.32K
Total Assets restated Q2 2024 · Dec 31, 2023 $19.6K
Eps Diluted Q2 2024 · Jun 30, 2024 $0.00
Eps Diluted Q2 2024 · Jun 30, 2024 $0.00
Eps Diluted Q2 2024 · Jun 30, 2023 $0.00
Eps Diluted Q2 2024 · Jun 30, 2023 $0.00
Eps Basic Q2 2024 · Jun 30, 2024 $0.00
Eps Basic Q2 2024 · Jun 30, 2024 $0.00
Eps Basic Q2 2024 · Jun 30, 2023 $0.00
Eps Basic Q2 2024 · Jun 30, 2023 $0.00
Sga Expense restated Q2 2024 · Jun 30, 2024 $40K
Sga Expense restated Q2 2024 · Jun 30, 2024 $61.72K
Sga Expense restated Q2 2024 · Jun 30, 2023 $21K
Sga Expense restated Q2 2024 · Jun 30, 2023 $21.87K
Net Income restated Q2 2024 · Jun 30, 2024 −$54.8K
Net Income restated Q2 2024 · Jun 30, 2024 −$114.03K
Net Income Q2 2024 · Jun 30, 2023 −$27.81K
Net Income Q2 2024 · Jun 30, 2023 −$47.38K
Operating Income restated Q2 2024 · Jun 30, 2024 −$54.8K
Operating Income restated Q2 2024 · Jun 30, 2024 −$114.03K
Operating Income Q2 2024 · Jun 30, 2023 −$27.81K
Operating Income Q2 2024 · Jun 30, 2023 −$47.38K
Revenue Q2 2024 · Jun 30, 2024 $156
Revenue Q2 2024 · Jun 30, 2024 $156